Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte(University of British Columbia), Michael R. Hayden(Family Research Institute), Jeffrey B. Carroll(Western Washington University), Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Crystal N. Doty(University of British Columbia), Holly Kordasiewicz(University of British Columbia), Kuljeet Vaid(University of British Columbia), Eugenia Petoukhov(University of British Columbia), Amber L. Southwell(University of Central Florida), Gene Hung(Ionis Pharmaceuticals (United States)), C. Frank Bennett(Pennsylvania State University), Punit P. Seth(Ionis Pharmaceuticals (United States)), Simon C. Warby(Stanford Medicine), Andrew T. Watt(University of British Columbia), Susan M. Freier(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States))
Cited by 114
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976